Navigation Links
Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors

BASKING RIDGE, N.J., Nov. 18, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the appointment of Pierre Legault, MBA, CA, CPA, to its Board of Directors, where he will serve as Chairman of the audit committee. 

Mr. Legault has extraordinarily broad executive management experience, including more than 30 years spent executing creative financing strategies, driving corporate development, and constructing value-driving transactions for international biotechnology and pharmaceutical companies.  In addition, Mr. Legault has significant experience serving on the board of directors and audit committees of public companies.

Mr. Legault is currently CEO of NephroGenex, a late-stage biotech company, and was previously Executive Chairman.  He is also President and CEO of Stone Management LLC, a firm focused in the areas of business development and board assistance.  From 2009 to 2012, he held leadership positions at Astellas Pharmaceuticals and its legacy companies, including Chief Executive Officer of Prosidion Ltd., and Executive VP, CFO and Treasurer of OSI Pharmaceuticals.  From January 2006 to December 2008, Mr. Legault worked for Rite Aid Corporation, a Fortune 500 publicly traded pharmaceutical retail company, most recently as senior executive vice president and chief administrative officer.  Prior to Rite Aid Corporation, Mr. Legault held several senior positions over 15+ years at Sanofi-Aventis and predecessor companies, serving most recently as Worldwide President of a large, global dermatology business unit.

In addition, Mr. Legault has served on several public, private and nonprofit company boards and audit committees, including Forest Laboratories, Inc., on which he serves currently as audit committee Chairman.  Prior board positions include OSI Investment Holdings GMBH (Chairman), Cyclacel Pharmaceutical Inc., PJC Inc., as well as other private boards.  Mr. Legault studied at the Harvard Business School in an executive masters program and he received his MBA from McGill University and his BAA from University of Montreal (HEC).  He also holds CA and CPA degrees.

Mr. Legault stated, "Throughout my career I have chosen board appointments very carefully, and I see a tremendous opportunity in Regado.  As the company continues to drive toward clinical success with REG1, I look forward to offering my expertise and guidance."

Dennis Podlesak, MBA, Regado's Board Chairman, stated, "We are very pleased to add Mr. Legault to our board of directors and as our audit committee Chairman.  We believe his specific expertise in this role will be a valuable asset for Regado, as will his impressive background in running international pharmaceutical companies across the full spectrum of clinical and commercial development." 

Regado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.  Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen.  REG1 is being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs.  More information can be found at

For more information on REGULATE-PCI, please visit:

Tiberend Strategic Advisors, Inc.

Investors - Joshua Drumm, Ph.D.; (212) 375-2664

Media - Andrew Mielach; (212) 375-2694

SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
2. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
3. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
4. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
5. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
6. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
7. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
8. Pressure BioSciences, Inc. Discusses Record Third Quarter Revenue, Strong Fourth Quarter Guidance, Significant Progress on New Instrument Systems, and Expectation to Pay-Off All Outstanding Convertible Notes at the SeeThruEquity Financial Conference
9. Jeeven BioSciences, Inc. Announces the Release of its Neuro-X(TM) Serum Free and Xeno Free Tissue Culture Media
10. SeeThruEquity, LLC Initiates Coverage on Pressure BioSciences, Inc.
11. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Post Your Comments:
(Date:10/13/2015)... 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV ... focused on the development and commercialization of targeted ... previously announced underwritten public offering of 5,000,000 shares ... up to 3,000,000 shares of the Company,s common ... public of $3.00. The shares of common stock ...
(Date:10/13/2015)... , Oct. 13, 2015  Human Longevity, Inc. (HLI), ... of medicine, announced today the launch of the company,s ... that has the potential to transform healthcare. The inaugural ... CA , at HLI,s headquarters facility. More Health ... other US and International cities. ...
(Date:10/13/2015)... 13, 2015  Measurement in accountable care programs ... financial incentives, but gaps in measurement can result ... health systems. A new, peer-reviewed study published ... explores measurement gaps for high-priority conditions ... --> --> "These ...
Breaking Medicine Technology:
(Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... ... of its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit . ... end. , ENGAGE delivers innovative health programs and interventions via mobile devices that ...
(Date:10/13/2015)... ... October 13, 2015 , ... ProText Kinetic Panel is a typography ... Kinetic Panel, users can create energetic text animations in any layout without the use ... Cut Pro X timeline and stylize the text. With intuitive on-screen controls, users can ...
(Date:10/13/2015)... ... , ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to announce that ... March 2nd and 3rd, 2016. The annual meeting, along with the Dallas Rhinoplasty ... around the world. , Key topics at this year's event will include discussions on ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an age where the cost of energy ... per square foot than in 2009. The Williamsport Regional Medical Center (WRMC) campus has ... decreased by eight percent. , According to Facilities Management Administrative Director Dieter Reichmann, ...
(Date:10/13/2015)... ... October 13, 2015 , ... Dr. Poneh Ghasri, dentist in ... September 18, 2015. The research, which was conducted at the Dental Institute at King's ... show connections between stress during pregnancy and future dental health in the child. For ...
Breaking Medicine News(10 mins):